"B7-H1 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitory B7 antigen that contains V-type and C2 type immunoglobulin domains. It has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN and provides negative signals that control and inhibit T-cell responses. It is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION.
| Descriptor ID |
D060890
|
| MeSH Number(s) |
D12.776.467.150.300 D12.776.543.095.300 D23.050.301.285.400 D23.529.168.300
|
| Concept/Terms |
B7-H1 Antigen- B7-H1 Antigen
- Antigen, B7-H1
- B7 H1 Antigen
- Programmed Cell Death 1 Ligand 1
- B7-H1 Immune Costimulatory Protein
- B7 H1 Immune Costimulatory Protein
- PD-L1 Costimulatory Protein
- Costimulatory Protein, PD-L1
- PD L1 Costimulatory Protein
- Programmed Cell Death 1 Ligand 1 Protein
- CD274 Antigen
- Antigen, CD274
- Antigens, CD274
- CD274 Antigens
- B7H1 Immune Costimulatory Protein
|
Below are MeSH descriptors whose meaning is more general than "B7-H1 Antigen".
Below are MeSH descriptors whose meaning is more specific than "B7-H1 Antigen".
This graph shows the total number of publications written about "B7-H1 Antigen" by people in this website by year, and whether "B7-H1 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 5 | 5 |
| 2006 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2012 | 2 | 1 | 3 |
| 2013 | 3 | 1 | 4 |
| 2014 | 4 | 3 | 7 |
| 2015 | 5 | 2 | 7 |
| 2016 | 7 | 5 | 12 |
| 2017 | 6 | 6 | 12 |
| 2018 | 11 | 9 | 20 |
| 2019 | 13 | 18 | 31 |
| 2020 | 16 | 14 | 30 |
| 2021 | 7 | 13 | 20 |
| 2022 | 2 | 14 | 16 |
| 2023 | 2 | 16 | 18 |
| 2024 | 10 | 11 | 21 |
| 2025 | 5 | 3 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "B7-H1 Antigen" by people in Profiles.
-
Digital Versus Manual PD-L1 Scoring in Advanced NSCLC From the IMpower110 and IMpower150 Trials. J Thorac Oncol. 2025 Dec; 20(12):1778-1790.
-
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1?
-
Tumor aneuploidy as a prognostic and predictive biomarker in immune checkpoint blockade. Nat Genet. 2025 Aug; 57(8):1802-1811.
-
Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody-STING agonist conjugates. Nat Biomed Eng. 2025 Oct; 9(10):1719-1739.
-
Adaptive immune response and PD-1/ PD-L1 status in chemotherapy treated high grade serous carcinoma is dependent on chemotherapy response score. Hum Pathol. 2025 May; 159:105800.
-
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1. J Thorac Oncol. 2025 Jul; 20(7):941-954.
-
Nanoparticle-Mediated Toll-Like Receptor Activation and Dual Immune Checkpoint Downregulation for Potent Cancer Immunotherapy. ACS Nano. 2025 03 11; 19(9):8852-8866.
-
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. J Immunother Cancer. 2025 Feb 04; 13(2).
-
NK cells restrain cytotoxic CD8+ T cells in the submandibular gland via PD-1-PD-L1. Sci Immunol. 2024 12 20; 9(102):eadl2967.
-
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025 Jan; 637(8048):1218-1227.
People
People who have written about this concept.
Explore
_
Similar Concepts
Similar concepts derived from published works.
_
Top Journals
Top journals in which articles about this concept have been published.